Last reviewed · How we verify
BDP Nasal Aerosol
BDP (beclomethasone dipropionate) is a corticosteroid that reduces inflammation in the nasal airways by suppressing immune responses and decreasing inflammatory mediator release.
BDP (beclomethasone dipropionate) is a corticosteroid that reduces inflammation in the nasal airways by suppressing immune responses and decreasing inflammatory mediator release. Used for Allergic rhinitis, Non-allergic rhinitis, Nasal inflammation and congestion.
At a glance
| Generic name | BDP Nasal Aerosol |
|---|---|
| Also known as | Beclomethasone dipropionate, QNASL® |
| Sponsor | Teva Branded Pharmaceutical Products R&D, Inc. |
| Drug class | Intranasal corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Allergy |
| Phase | Phase 3 |
Mechanism of action
Beclomethasone dipropionate is a topical corticosteroid that binds to glucocorticoid receptors in nasal tissue, inhibiting the production of inflammatory cytokines and reducing recruitment of inflammatory cells. This mechanism reduces nasal inflammation, congestion, and associated symptoms in allergic and non-allergic rhinitis. The nasal aerosol formulation delivers the drug directly to nasal mucosa for local anti-inflammatory effects.
Approved indications
- Allergic rhinitis
- Non-allergic rhinitis
- Nasal inflammation and congestion
Common side effects
- Headache
- Nasal irritation
- Epistaxis (nosebleed)
- Pharyngitis
- Dysgeusia (altered taste)
Key clinical trials
- Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013) (PHASE3)
- Dose-Ranging Study of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (C95-161) (PHASE3)
- Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR) (PHASE3)
- Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis (PHASE3)
- Nebulized Beclometasone Dipropionate Improves Nasal Patency in Children With Allergic Rhinitis (PHASE4)
- Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients With Perennial Allergic Rhinitis (PAR) (BY9010/M1-408) (PHASE3)
- Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR) (PHASE3)
- Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Perennial Allergic Rhinitis (PAR) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BDP Nasal Aerosol CI brief — competitive landscape report
- BDP Nasal Aerosol updates RSS · CI watch RSS
- Teva Branded Pharmaceutical Products R&D, Inc. portfolio CI